Why is Curis stock surging 70% today?
Curis (CRIS) stock surged 70.7% pre-market to $1.2188 ahead of a Nov. 18 shareholder vote on a reverse stock split, which the board says is needed to avoid Nasdaq delisting. The company also awaits clinical trial data and earnings. Low trading volume amplified the move.
How this was made
The 30-second read
Why it matters
The proxy filing and imminent reverse split vote provide a concrete catalyst that can materially affect the stock price in the short term.
Market read
The article introduces a fresh corporate‑action catalyst for a microcap biotech, creating a short‑term trading opportunity.
What to watch
Potential dilution from future capital raises and the uncertainty of upcoming clinical data.
Background
Curis (CRIS) is a thinly traded biotech whose share price is highly sensitive to corporate‑action news and clinical milestones.
Ticker impact
Curis filed a definitive proxy statement scheduling a shareholder vote on a reverse stock split, driving a 70% pre‑market surge.
likely upward pressure as investors buy ahead of the split vote
Reverse split can lift the price above Nasdaq's $1 minimum, attracting new investors and reducing delisting risk.
Market effects
Biotech sector may see heightened speculative activity in low‑float stocks with corporate‑action catalysts.
US Nasdaq‑listed microcaps could experience similar volatility ahead of compliance‑driven actions.
Limited to US‑listed biotech investors; no broader macro impact.
Counterpoint
If the split fails or is delayed, the stock could sharply reverse its rally.
Key entities
- companyCuris, Inc.
US‑listed biotech facing a reverse stock split vote.

